donor. 1 Alternative donor sources for allogeneic transplantation include partially matched related donors (PMRD) or unrelated donors (URD). Each source has limitations; The results of partially matched related donor (PMRD) marrow transplantation for 82 patients with leukemia neither is clearly preferred when marrow from an HLAmatched sibling is unavailable. are reported, including 45 who received two antigen disparate grafts. Following intensive radiochemotherapy, Unlike many cases of URD transplants, a partially matched related donor transplant can often be performed patients received grafts which were partially depleted of T cells by the monoclonal antibody T10B9 and comppromptly, as most siblings will have been tissue typed in an attempt to find a histocompatible donor. While the National lement. Actuarial probability of engraftment was 86% (95% CI = 78-93%). The median day to engraftment Marrow Donor Program (NMDP) has reported success in finding a serologically matched unrelated donor for 51% of was similar among recipients of grafts disparate at one, two or three antigen loci. The incidence of severe patients, 2 the median interval between search initiation and transplantation was 208 days (range 16-1392 days).
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tation at the University of Kentucky. None of these patients selection of the donor was made according to previously published guidelines. 12, 13 had an HLA-matched sibling donor. Additional eligibility criteria included the presence of a suitable related haploidentical donor, age р50 years, the absence of life-threatenTransplant procedure ing infection, and near normal cardiac, hepatic, pulmonary and renal function. Relapse and survival at the date of last Patients were conditioned prior to transplantation with total body irradiation, 1400 cGy in nine fractions (dose rate of contact were analyzed as of April 1995. Median follow-up of surviving patients is 5 years (range 3-7 years). Patient 12.5 cGy/min) over 3 days using a high energy linear accelerator beginning on day −9 and continuing to day −7. Total characteristics are shown in Table 2 .
lung doses were reduced to 700 cGy by 50% transmission blocks.
Donor-recipient HLA compatability/donor selection
Subsequently, etoposide (20 mg/kg) was given on day −6, cytarabine (3 g/m 2 every 12 h for six doses) on days Patients and donors were HLA typed according to standard techniques.
11 HLA A, B, and DR data are complete for 81 −4, −3 and −2, and cyclophosphamide (50 mg/kg) on days −2 and −1. Methylprednisolone (1 mg/m 2 ) was started at of 82 patients. DR typing is incomplete for two patients. The degree of donor-recipient HLA-disparity is shown in 8.00 pm on day −2 and continued every 12 h for four total doses. All doses were calculated utilizing the patient's ideal Table 1 .
Among family members who were potentially PMRDs, body weight. The mean number of mononuclear cells harvested was 6.61 × 10 8 /kg of recipient body weight (range preference was given to the family member who most closely matched the patient. If more than one family mem-1.78-19.00).
The mean number of mononuclear cells infused was ber was available for marrow donation using this criteria, 1.11 × 10 8 /kg recipient body weight (range 0.32-5.22). Marrow grafts were partially depleted ex vivo of T cells with monoclonal antibody T10B9 (1A-31) and rabbit serum defined as early disease. Patients with acute leukemia in any remission other than first, and CML patients in accelerthe patients transplanted with grafts disparate at one, two, and three antigen loci. ated phase were considered to have intermediate disease.
Advanced disease patients had refractory leukemia, relapsed leukemia, or CML in blast crisis. Patients with Engraftment myelodsyplasia without evolution to acute leukemia were deemed to have early disease, while those with 30% marEight patients who died before day +21 were excluded from the engraftment analysis. Of the 74 remaining patients, 10 row blasts were classified as advanced. Remission was defined as an M1 marrow (Ͻ5% blasts), normal cytogenfailed to engraft. Two of these 10 patients subsequently engrafted after marrow boosts. Interestingly, nine of those etics and normal flow cytometry.
failing to engraft were transplanted for chronic myelogenous leukemia.
Statistical methods
The median day to engraftment for the remaining 64 patients was 18 days (range 7-35 days). The actuarial probActuarial probabilities of overall survival and disease-free survival were calculated using standard life-table ability of engraftment by day 14 post-transplant was 86% (95% CI = 78-93%), and was not affected by the overall methods. 16 Comparison between groups was performed using the Wilcoxon test.
17 Kaplan-Meier curves were anadegree of HLA disparity between the donor and the recipient or the HLA disparity in the rejection direction lyzed to determine the effect of age, degree of HLA disparity, and disease state on overall survival and disease-free (Figure 1 ). survival. Rates of non-engraftment, the median time to engraftment, the effect of HLA disparity on engraftment, Acute and chronic GVHD the incidence of aGVHD and cGVHD according to the degree of HLA disparity are reported. The 2 goodness of The 66 patients who engrafted were analyzed for aGVHD. 
Patient characteristics
We analyzed the effect of various GVHD prophylaxis Characteristics of those transplanted are reported in Table  regimens in the 45 patients transplanted with grafts dispar-1. Thirty of the 82 patients were less than age 16. However, ate at two loci. Twenty-four of these patients received 26 patients were older than 30 at the time of transplant and immunotoxin-ricin A chain prophylaxis, 20 received cyclo-11 were age 40 or older. Only 10 patients (12%) had early, sporine prophylaxis, and one received both. The incidence while 29 patients (35%) had intermediate, and 43 (52%) of severe (grade III or IV) aGVHD was similar in the group had advanced stage disease.
receiving immunotoxin and the cyclosporine-treated group All patients received grafts which were mismatched (P = 0.877). genotypically, in one case, the donor was phenotypically All patients alive at day 100 post-transplant (n = 45) were matched, and in two cases, DR typing was incomplete (of evaluable for chronic GVHD. Forty-seven patients of day these two patients, one was matched at both the A and B 100 survivors had no evidence of cGVHD, 47% developed loci, while the other was mismatched at A and matched at limited and 6% had extensive cGVHD. The incidence of B). Of the remaining 79 patients, 14 received grafts which were one antigen disparate, 45 received two antigen disparate grafts and 20 received three antigen disparate grafts. Table 2 contains age, and disease status characteristics of plant.
cGVHD was not affected by the degree of HLA disparity Relapse between the donor and the recipient.
The probability of relapse during the first 3 years after PMRD BMT (see Figure 2 ) is 30% (95% CI = 17-43%).
Non-relapse mortality
With a median follow-up of 4.1 years, 18 patients have relapsed (only one patient with early disease, six patients Non-relapse mortality occurred only in the 1st year after with intermediate disease and 11 patients with advanced transplant with a probability of 47% (95% CI = 42-64%, disease). While the impact of disease status at the time of Figure 2 ). Fifty-three of the 82 patients died. The major transplantation did not reach statistical significance, a trend transplant-related causes of death were infection (n = 10), was demonstrated, with advanced disease patients having a aGVHD (n = 7), cGVHD (n = 3), non-engraftment (n = greater likelihood of relapse than those transplanted with 9). Another three patients died of bleeding, four of venoeither early or intermediate disease (P = 0.06). The degree occlusive disease, and three of other causes. Among those of HLA disparity between patient and donor did not have 10 patients dying of infection, three died of bacterial sepsis, a significant effect on the risk of relapse (data not shown). one of bacterial meningitis, one of disseminated candidi-
Disease-free survival and survival
The probability of disease-free survival after PMRD BMT (see Figure 3 ) is 31% at 3 years (95% CI = 26-46%). The likelihood of surviving free of disease after PMRD BMT was influenced by age, disease status at time of transplant, and degree of disparity of the graft received (see Table 4 ). Table 4 Relapse-free survival. Survivors/number transplanted Disease-free survival was significantly longer for those The probability of disease-free survival was higher for patients with early or intermediate stage disease at the time transplanted at age р30 years than for those transplanted at age Ͼ30 (P = 0.004) (Figure 4) . Analysis of two subsets of transplantation than for those transplanted with advanced disease (P = 0.03) (see Figure 4) . However, even patients of patients transplanted at age 0-16 and 17-30 revealed no difference in disease-free survival.
transplanted with advanced disease (including patients with refractory leukemia) had a probability of disease-free survival of approximately 22% (95% CI = 10-35%). The probability of 3-year disease-free survival for patients receiving marrow mismatched at one locus was 53%, 36% for patients receiving marrow mismatched at two loci, and 5% for patients receiving marrow mismatched at three loci (Figure 4) . Results achieved within each subset of patients were affected by the age and disease status of patients at the time of transplantation.
Detailed results of the 45 patients receiving two antigen disparate grafts are as follows: 13 of the 30 patients age р30 years at transplantation remain alive and free of disease, while only three of 15 patients transplanted at age Ͼ30 survived. Nineteen of these 45 patients had early/intermediate disease at the time of transplantation; nine survive. Of the 26 transplanted with advanced disease only seven survive (six were рage 30). Only nine patients in the two antigen disparate subset had both favorable pretransplant characteristics (age р30 and disease of either early or intermediate type). Seven of these patients remain alive.
All patients receiving three antigen disparate grafts had either intermediate or advanced disease. Only three of these 20 patients remain alive. Nine of these 20 patients were age Ͼ30 at the time of transplantation.
The overall probability of 3-year survival after PMRD BMT was 35% (95% CI = 24.5%-45.3%) (see Figure 3) . The mean survival for patients with advanced disease was 13 weeks compared to 61 months for those with early or intermediate disease.
Discussion
TCD PMRD transplantation offers a 35% probability of long-term disease-free survival to patients with leukemia. The frequency of nonengraftment, acute and chronic GVHD, death due to transplant-related toxicities, and relapse have been reported.
4-9
The actuarial probability of graft failure in our series was 14%. Interestingly, we were unable to demonstrate that the rate of non-engraftment or the median time to engraftment was increased with increasing graft HLA disparity. These results are at odds with those of other investigators.
6,9 The small numbers of patients transplanted in our series may prevent us from having the statistical power to demonstrate the effect of HLA disparity on engraftment with statistical significance.
The incidence of aGVHD and cGVHD in our series is acceptable. One antigen disparate PMRD BMT is performed frequently at several institutions. We transplanted 15 patients with this degree of HLA disparity; only one experienced severe (grade III or IV) aGVHD. Thirty-four of 45 severe aGVHD. This incidence was not significantly differ-
